Table 6 Combination of target therapy and immunotherapy
NCT No. | Drug 1 | Drug2 | Conditions | Phase | region | Start year | results |
|---|---|---|---|---|---|---|---|
NCT03149120 | Nivolumab | Pazopanib | Soft Tissue Sarcomas | Phase II | US | 2017 | No |
NCT03190174 | Nivolumab | Rapamycin | Undifferentiated Pleomorphic Sarcoma|Liposarcoma|Chondrosarcoma|Osteosarcoma|Ewing Sarcoma | Phase I| Phase II | US | 2017 | No |
NCT02636725 | Pembrolizumab | Axitinib | Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas | Phase II | US | 2016 | No |
NCT03359018 | Camrelizumab | Apatinib | osteosarcoma | Phase II | Asia | 2018 | No |
NCT03277924 | Nivolumab | Sunitinib | Soft Tissue Sarcoma|Bone Sarcoma | Phase I| Phase II | Europe | 2017 | No |